Englewood Cliffs, NJ – According to filings with the U.S. Securities and Exchange Commission, Aspargo Laboratories is raising $8,500,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Michael Demurjian played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aspargo Laboratories

Aspargo Laboratories, Inc. is a clinical stage pharmaceutical company focused on developing an oral spray formulation of sildenafil, the active ingredient in Viagra, in the United States. Aspargo is the exclusive U.S. licensee of the U.S. patent rights covering Sildenafil Oral Spray.

To learn more about Aspargo Laboratories, visit http://aspargolabs.com/

Contact:
Michael Demurjian, Chief Executive Officer
201-408-4831
https://www.linkedin.com/in/michael-demurjian-02868113/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved